Biochemistry of the lysine beta-hydroxybutyrylation pathway
赖氨酸β-羟基丁酰化途径的生物化学
基本信息
- 批准号:10210387
- 负责人:
- 金额:$ 53.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAcetyltransferaseAffinityAlcoholic liver damageAreaBinding ProteinsBiochemistryBiologicalBiological ProcessBiologyBrainCell physiologyCellsChemicalsCoenzyme AComplications of Diabetes MellitusCouplesDNADataData SetDeacetylaseDiabetes MellitusDiabetic DietDiseaseEnergy MetabolismEnzymatic BiochemistryEnzymesEpigenetic ProcessFoundationsFunctional disorderGene ExpressionGenesGoalsHistone DeacetylaseHistonesHydroxybutyratesIn VitroInfrastructureInsulin-Dependent Diabetes MellitusKetone BodiesLabelLaboratoriesLeadLibrariesLinkLiverLysineMass Spectrum AnalysisMediatingMetabolic PathwayMetabolismMethodsModificationMolecularMolecular BiologyMorbidity - disease rateNutrientObesityOutputPathologicPathway interactionsPatientsPeptide LibraryPeptidesPhysiologicalPlasmaPositioning AttributePost-Translational Protein ProcessingProteinsProteomicsRecombinant ProteinsRecombinantsRegulatory ElementResearchRiskSerumSolidSourceStarvationTestingTherapeuticTissuesTransfectionWestern Blottinganti-cancerbasebeta-Hydroxybutyratecancer clinical trialexperimental studyhistone modificationimprovedin vitro Assayin vivoinsightmortalitymouse modelnovelnutritionprogramspromoterresponse
项目摘要
Emerging lines of evidence suggest a close link between obesity, energy metabolism, nutrients and epigenetic
mechanism. Epigenetic changes, such as dynamic histone modifications, are associated with cellular
metabolism and diabetic complications. Nevertheless, the molecular mechanisms mediating the crosstalk
between metabolism and epigenetics remain incompletely understood. We recently discovered and
comprehensively validated a new, evolutionarily-conserved lysine modification, lysine beta(β)-
hydroxybutyrylation (Kbhb), on core histones. We detected 44 non-redundant Kbhb marks on histones and
identified Sirt2 enzyme as the first enzyme to remove histone Kbhb. Levels of Kbhb are very dynamic and are
influenced by physiological conditions (e.g., starvation and type I diabetes) and nutrition sources. Increased
levels of β-hydroxybutyrate (also called 3-hydroxybutyrate) lead to increased histone Kbhb, presumably via
conversion of β-hydroxybutyrate to β-hydroxybutyryl CoA. Interestingly, histone Kbhb is enriched in active
gene promoters, and the increased H3K9bhb levels that occur during prolonged starvation are associated with
genes up-regulated in starvation-responsive metabolic pathways, thus representing a new epigenetic
regulatory mark that couples metabolism to gene expression. β-Hydroxybutyrate is a key component of
“ketone bodies” and it has been employed in dozens of anti-cancer clinical trials as a potential therapeutic in
combination with other agents. The plasma/cellular concentration of β-hydroxybutyrate can increase up to 20
mM during starvation and in pathological conditions such as diabetes mellitus (DM) and alcoholic liver damage
and this can drive histone Kbhb formation. Hyperketonemia and ketoacidosis are known to increase the risk of
morbidity and mortality in patients. Thus, molecular characterization of Kbhb pathway will not only improve our
understanding of epigenetic mechanism but also characterize functions of β-hydroxybutyrate in
physiopathology. We hypothesize that the Kbhb pathway is molecularly distinct from the lysine acetylation
pathway. We therefore propose to characterize the Kbhb pathway by defining its key regulatory elements,
including its substrates, a unique set of regulatory enzymes and direct binding proteins, thus laying a
foundation for studying its biology functions. We will use an integrated strategy in this study involving
enzymology, chemical biology, biochemistry and proteomics approaches. Our team, the Zhao laboratory and
the Cole laboratory, is well positioned to carry out this project, because of our combined expertise in these
areas and the relevant preliminary data that we have already obtained. In this proposal, we will first
comprehensively identify and quantify dynamic changes of Kbhb-containing substrates using a quantitative
proteomics approach. We will then identify and characterize Kbhb-regulatory enzymes that can add or remove
Kbhb. We will finally identify and confirm the direct protein binders of histone Kbhb peptides.
新出现的证据表明,肥胖、能量代谢、营养和表观遗传之间存在密切联系。
机制表观遗传学变化,如动态组蛋白修饰,与细胞增殖有关。
代谢和糖尿病并发症。然而,介导串扰的分子机制
代谢和表观遗传学之间的联系仍然不完全清楚。我们最近发现,
全面验证了一种新的、进化上保守的赖氨酸修饰,赖氨酸β(β)-
核心组蛋白上的羟基丁酰化(Kbhb)。我们在组蛋白上检测到44个非冗余Kbhb标记,
鉴定Sirt 2酶为第一种去除组蛋白Kbhb的酶。Kbhb的水平非常动态,
受生理条件的影响(例如,饥饿和I型糖尿病)和营养来源。增加
β-羟基丁酸酯(也称为3-羟基丁酸酯)水平导致组蛋白Kbhb增加,可能是通过
β-羟基丁酸转化为β-羟基丁酰辅酶A。有趣的是,组蛋白Kbhb富含活性
基因启动子,以及在长期饥饿期间发生的H3 K9 bhb水平增加与
在饥饿反应代谢途径中上调的基因,因此代表了一种新的表观遗传学。
将新陈代谢与基因表达结合的调节标记。β-羟基丁酸酯是
“酮体”,它已被用于几十个抗癌临床试验,作为一种潜在的治疗,
与其他代理商的组合。β-羟基丁酸酯的血浆/细胞浓度可增加至20
在饥饿和病理条件下,如糖尿病(DM)和酒精性肝损伤
这可以驱动组蛋白Kbhb的形成。已知高酮血症和酮症酸中毒会增加以下风险:
患者的发病率和死亡率。因此,Kbhb途径的分子表征不仅将改善我们的研究,
了解表观遗传机制,但也表征β-羟基丁酸在
生理病理学我们假设Kbhb途径在分子上不同于赖氨酸乙酰化
通路因此,我们建议通过定义其关键调控元件来表征Kbhb途径,
包括其底物,一套独特的调节酶和直接结合蛋白,从而奠定了
为研究其生物学功能奠定了基础。在这项研究中,我们将采用一种综合战略,
酶学、化学生物学、生物化学和蛋白质组学方法。我们的团队,Zhao实验室和
科尔实验室,是很好的定位,以执行这一项目,因为我们的综合专业知识,在这些
以及我们已经获得的有关初步数据。在这份提案中,我们将首先
使用定量分析方法全面识别和量化含KbHb底物的动态变化,
蛋白质组学方法。然后,我们将确定和表征KbHb调节酶,可以添加或删除
Kbhb。我们将最终确定和确认组蛋白Kbhb肽的直接蛋白结合剂。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Class I histone deacetylases (HDAC1-3) are histone lysine delactylases.
- DOI:10.1126/sciadv.abi6696
- 发表时间:2022-01-21
- 期刊:
- 影响因子:13.6
- 作者:Moreno-Yruela C;Zhang D;Wei W;Bæk M;Liu W;Gao J;Danková D;Nielsen AL;Bolding JE;Yang L;Jameson ST;Wong J;Olsen CA;Zhao Y
- 通讯作者:Zhao Y
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILIP A COLE其他文献
PHILIP A COLE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILIP A COLE', 18)}}的其他基金
Chemical Approaches to Understanding Reversible Lysine Modifications
理解可逆赖氨酸修饰的化学方法
- 批准号:
10621611 - 财政年份:2023
- 资助金额:
$ 53.31万 - 项目类别:
FASEB SRC on Reversible Acetylation in Health and Disease
FASEB SRC 关于健康和疾病中的可逆乙酰化
- 批准号:
9750429 - 财政年份:2019
- 资助金额:
$ 53.31万 - 项目类别:
Mechanistic Studies of EGFR/ErbB Receptor Tyrosine Kinases
EGFR/ErbB 受体酪氨酸激酶的机制研究
- 批准号:
8606747 - 财政年份:2012
- 资助金额:
$ 53.31万 - 项目类别:
Mechanistic Studies of EGFR/ErbB Receptor Tyrosine Kinases
EGFR/ErbB 受体酪氨酸激酶的机制研究
- 批准号:
8795729 - 财政年份:2012
- 资助金额:
$ 53.31万 - 项目类别:
Mechanistic Studies of EGFR/ErbB Receptor Tyrosine Kinases
EGFR/ErbB 受体酪氨酸激酶的机制研究
- 批准号:
8436210 - 财政年份:2012
- 资助金额:
$ 53.31万 - 项目类别:
Mechanistic Studies of EGFR/ErbB Receptor Tyrosine Kinases
EGFR/ErbB 受体酪氨酸激酶的机制研究
- 批准号:
8310660 - 财政年份:2012
- 资助金额:
$ 53.31万 - 项目类别:
Development and Application of Ghrelin O-acyltransferase Inhibitors
Ghrelin O-酰基转移酶抑制剂的开发及应用
- 批准号:
8215389 - 财政年份:2011
- 资助金额:
$ 53.31万 - 项目类别:
TCP5: ACTIVE SITE LABELING REAGENT FOR ACETYLTRANSFERASES
TCP5:乙酰转移酶活性位点标记试剂
- 批准号:
7724689 - 财政年份:2008
- 资助金额:
$ 53.31万 - 项目类别:
TCP5: ACTIVE SITE LABELING REAGENT FOR ACETYLTRANSFERASES
TCP5:乙酰转移酶活性位点标记试剂
- 批准号:
7622843 - 财政年份:2007
- 资助金额:
$ 53.31万 - 项目类别:
相似海外基金
Dissecting out differential molecular phenotypes across Lysine(K) AcetylTransferase mutations in mouse development
剖析小鼠发育过程中赖氨酸(K)乙酰转移酶突变的差异分子表型
- 批准号:
10727966 - 财政年份:2023
- 资助金额:
$ 53.31万 - 项目类别:
Targeting lysine acetyltransferase MOF/KAT8 in lung cancer
靶向赖氨酸乙酰转移酶 MOF/KAT8 在肺癌中的作用
- 批准号:
10601761 - 财政年份:2023
- 资助金额:
$ 53.31万 - 项目类别:
Defining the cell-type specific role of histone acetyltransferase KAT2a in nucleus accumbens D1 medium spiny neurons as a driver of cocaine use disorder
定义组蛋白乙酰转移酶 KAT2a 在伏隔核 D1 中型多棘神经元中作为可卡因使用障碍驱动因素的细胞类型特异性作用
- 批准号:
10679238 - 财政年份:2023
- 资助金额:
$ 53.31万 - 项目类别:
Roles of lysine acetyltransferase 6 complexes in cerebral development and neurodevelopmental disorders
赖氨酸乙酰转移酶 6 复合物在大脑发育和神经发育障碍中的作用
- 批准号:
479754 - 财政年份:2023
- 资助金额:
$ 53.31万 - 项目类别:
Operating Grants
Examination of the Histone Acetyltransferase CBP in the Remodelling of Thermogenic Adipose Tissues
组蛋白乙酰转移酶 CBP 在生热脂肪组织重塑中的检测
- 批准号:
486467 - 财政年份:2022
- 资助金额:
$ 53.31万 - 项目类别:
Studentship Programs
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
- 批准号:
10344246 - 财政年份:2022
- 资助金额:
$ 53.31万 - 项目类别:
Nuclear activity of carnitine acetyltransferase
肉毒碱乙酰转移酶的核活性
- 批准号:
RGPIN-2018-06089 - 财政年份:2022
- 资助金额:
$ 53.31万 - 项目类别:
Discovery Grants Program - Individual
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
- 批准号:
10627744 - 财政年份:2022
- 资助金额:
$ 53.31万 - 项目类别:
Structural and functional studies of histone acetyltransferase complexes
组蛋白乙酰转移酶复合物的结构和功能研究
- 批准号:
RGPIN-2018-03951 - 财政年份:2022
- 资助金额:
$ 53.31万 - 项目类别:
Discovery Grants Program - Individual
Characterizing the role of the NuA3 histone acetyltransferase complex during transcription
表征 NuA3 组蛋白乙酰转移酶复合物在转录过程中的作用
- 批准号:
557615-2021 - 财政年份:2022
- 资助金额:
$ 53.31万 - 项目类别:
Postdoctoral Fellowships